2026 MaTOS GU | Session IV | Keynote Presentation
Overview
Dr. Tagawa reviewed RLT/TRT in prostate cancer: radium-223 and lutetium show benefit; combos promising, but more data needed on survival and long-term outcomes. The panel discussed RLT in prostate cancer: patient selection, sequencing, and long-term risks (MDS/AML) are key; trials exploring de-escalation and timing strategies.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Panelists:
Chandler H. Park, MD, MSc
Maha Hussein, MD
Daniel P. Petrylak, MD
Scott Tagawa, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
